Skip to search formSkip to main contentSkip to account menu

ARRY-614

Known as: Multikinase Inhibitor ARRY614 
An orally bioavailable small-molecule inhibitor of p38 and Tie2 kinases with potential antineoplastic, anti-inflammatory and antiangiogenic… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pexmetinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel…
Background Pexmetinib (ARRY-614) is a dual inhibitor of p38 mitogen-activated protein kinase and Tie2 signaling pathways… 
2015
2015
p38 MAPK in MDS
Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic malignancies occurring mainly in the elderly and… 
2013
2013
Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes
Background Emerging data support a role for both p38 MAPK (p38) and Tie2 in the molecular mechanisms underlying MDS… 
2012
2012
Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614.
Abstract 2825 Myelodysplastic syndromes (MDS) are a heterogeneous collection of disorders characterized by dysfunctional bone… 
2011
2011
Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes
Abstract 118 Background: Myelodysplastic syndromes (MDS) are characterized by excess elaboration of myelosuppressive cytokines… 
2007
2007
Activity of ARRY-614, an Inhibitor of p38 Map Kinase and Angiogenic Targets, in Hematologic Malignancies.
Multiple Myeloma (MM) is a malignancy characterized by the clonal expansion of plasma cells within the bone marrow… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)